Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03483597
Recruitment Status : Unknown
Verified March 2018 by Xiaofeng Zeng, Chinese SLE Treatment And Research Group.
Recruitment status was:  Not yet recruiting
First Posted : March 30, 2018
Last Update Posted : March 30, 2018
Sponsor:
Information provided by (Responsible Party):
Xiaofeng Zeng, Chinese SLE Treatment And Research Group

Brief Summary:
A questionnaire for this research is designed, which initiated from TSQM-II treatment satisfaction questionnaire and based on research launched by rheumatology and immunology departments of Chinese 12 public tertiary hospitals distributed directionally by Chinese Rheumatism Data Center (CRDC). The research is about treatment satisfaction and its influencing factors for Chinese rheumatoid immunologists and rheumatoid arthritis (RA) patients as well as their expectations for treating this disease. This research will explore the matching degree between treatment satisfaction and expectation about rheumatoid arthritis from doctors and patients.

Condition or disease Intervention/treatment
Rheumatoid Arthritis Satisfaction Other: TSQM-II

Detailed Description:
In the last decade, China has made quick progress on treatment of rheumatoid arthritis. However, the improvement of remission rate cannot fully represent needs of patients for health. To meet health demands of patients and improve their satisfaction, an efficacy evaluation system based on the outcome report of patients should be established. A questionnaire for this research is designed and mended in view of TSQM-II treatment satisfaction questionnaire and the actual situation of RA diagnosis and treatment in China. An investigation on treatment satisfaction and its influencing factors for Chinese rheumatoid immunologists and rheumatoid arthritis (RA) patients as well as their expectations for this disease is carried out based on 120 rheumatoid immunologists and 1,200 rheumatoid arthritis patients (1:10) from Chinese 12 public tertiary hospitals distributed directionally by Chinese Rheumatism Data Center (CRDC). The research concludes rheumatoid specialist physicians for doctor population, and persons aged over 18 for patient population who has been confirmed as RA for 6 months above, excluding patients with Chinese reading comprehension barriers or without any RA treatment. Finally, summarize and analyze the total score of satisfaction from doctors and patients, average score of doctors and patients for various medical demands, as well as the satisfaction of patients about communication and service during medical treatment.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1100 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Day
Official Title: The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis
Estimated Study Start Date : March 31, 2018
Estimated Primary Completion Date : April 30, 2018
Estimated Study Completion Date : April 30, 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
rheumatologists
Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
Other: TSQM-II
Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups

patients
Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
Other: TSQM-II
Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups




Primary Outcome Measures :
  1. Total score of patient satisfaction [ Time Frame: 1 day ]
    Total score of patient satisfaction


Secondary Outcome Measures :
  1. Average score of patients for various treatment demands [ Time Frame: 1 day ]
    Average score of patients for various treatment demands

  2. Average score of patients for long-term treatment demands [ Time Frame: 1 day ]
    Average score of patients for long-term treatment demands

  3. Average score of patients for new drug demands [ Time Frame: 1 day ]
    Average score of patients for new drug demands

  4. Total score of doctor satisfaction [ Time Frame: 1 day ]
    Total score of doctor satisfaction

  5. Average score of doctors for various treatment demands [ Time Frame: 1 day ]
    Average score of doctors for various treatment demands

  6. Average score of doctors for long-term treatment demands [ Time Frame: 1 day ]
    Average score of doctors for long-term treatment demands

  7. Average score of doctors for new drug demands [ Time Frame: 1 day ]
    Average score of doctors for new drug demands



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Subjects come from 12 hospitals in Chinese Rheumatism Data Center.
Criteria

Inclusion Criteria:

Doctors - registered rheumatoid specialist physicians subordinated to the 12 designated hospitals Patients - aged over 18, confirming RA for more than 6 months

Exclusion Criteria:

Doctors - N/A Patients - with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03483597


Contacts
Layout table for location contacts
Contact: Mengtao Li, MD +86-10-65296114 mengtao.li@cstar.org.cn
Contact: Nan Jiang, MD +86-10-65124875 jn_pumc@163.com

Sponsors and Collaborators
Chinese SLE Treatment And Research Group
Investigators
Layout table for investigator information
Study Chair: Xiaofeng Zeng, Doctor Director of Rheumatology and Immunology Department Chinese Academy of Medical Sciences &Peking Union Medical College Hospital

Additional Information:

Layout table for additonal information
Responsible Party: Xiaofeng Zeng, Director of Rheumatology and Immunology Department Chinese Academy of Medical Sciences &Peking Union Medical College Hospital, Chinese SLE Treatment And Research Group
ClinicalTrials.gov Identifier: NCT03483597    
Other Study ID Numbers: CRDC-satisfaction
First Posted: March 30, 2018    Key Record Dates
Last Update Posted: March 30, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases